VX-770
Jump to navigation
Jump to search
Indications
- treatment of cystic fibrosis (with G551D mutation of CTFR)
Dosage
Adverse effects
- macular rash
- deterioration of glycemic control in diabetes
Mechanism of action
- potentiates function of CTFR
More general terms
References
- ↑ Accurso FJ et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010 Nov 18; 363:1991. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21083385
Welsh MJ. Targeting the basic defect in cystic fibrosis. N Engl J Med 2010 Nov 18; 363:2056. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21083391